A HER 1-2 Punch: Dual EGFR targeting deals resistance a deadly blow

Abstract

Ten years after the approval of erlotinib, EGFR inhibitor resistance remains a major clinical challenge. The translation of afatinib plus cetuximab into the clinic provides a promising new option for the treatment of patients with EGFR-mutated lung cancer. © 2014 American Association for Cancer Research.